We would like to inform you that, the Board of Directors of the Company at their meeting held today i.e. 29th October, 2026 has, inter alia considered and approved Unaudited Financial Results (as per IND-AS) for the quarter and half year ended on 30th September, 2026. Enclosed herewith a copy of the same along with a copy of Limited Review Report dated 29th October, 2026 received from Vora & Associates, Chartered Accountants, Statutory Auditors ....

Colinz 29tr October,2O26 Bombay Stock Exchange Limited Phiroze eejeebhoY Towers, Dalal Street, Mumbai - 400001 Dear Sir Sub outcome of the Board Meeting under Regulation 30 and 33 of SEBi (Listing Obtigation and Disclosure Requirements) Regulations. 2015. BSE Code: 531210 we would like to inform you that, the Board of Directors of the company at their meeting held today i.e. }gtr_ october, 2026 has, inter alia considered and approved Unaudited Financial Results (as per IND-AS) for the quarter and half year ended on 30th SePtember,2026' Enclosed herewith a copy of the same along with a copy of Limited Review Report dated 29tr octob et, 2o26 received from Vora & Associates' chartered Accountants, Statutory Auditors of the Company with respect to Unaudited Financial Results for the quarter and half year ended on 30th September'2O26' TheMeetingcommencedat3:30PMandconcludedat5.30p.m. This is for your information and record' Thanking you, Yours faithfully, FOR COLINZ LABORATORIES LTD r-i i;iUii,iEAl VIJAYA MANI DIRECTOR DIN:11363910 Laboratories Limited CIN NO- L242OOMH1 986PLCO 41 128 Corp.Off.: l/101 , Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com Mobile :9137392123 VORA &'ASSOCIATES " 91-99305 75933 \. 022-22031110 INDIA CHARTERED ACCOUNTANTS www.cavoras.com lEI office@cavoras.com 101-103. REWA CHAMBERS. 31. NEW MARINE LINES. MUMBAI _ 400 020. cavoras@gmail.com Independent Auditor's Review Report on Unaudited Quarterly Financial Results The Board of Directors, COLINZ LABORATORIES LIMITED. We have reviewed the accompanying statement of unaudited financial results Cthe Statement') of COLINZ LABORATORIES LIMITED Cthe Company') for the quarter and half year ended 30th ~eptember, 2026 being submitted by the Company pursuant to the requirements of Regulation 33'ofthe SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) . . This statement, which is the responsibility of the Company's Management and has been approved by the Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting CInd AS 34) prescribed u/s 133 of the Companies Act, 2013 Cthe Act'), SEBI Circular CIR/CF /FAC/62/2016 dated 05/07/2016 (hereinafter referred to as the 'the SEBI Circular') and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review. We conducted our review of. the Statement in accordance with the Standard on Review Engagement (SRE) 2410· "Review of Interim Financial Statements Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Act read with relevant Rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement. ~""''''''oFC>. RAMBHIA PARTNER (Membership No.: 140371) UDIN: 26140371RLAFPR5809 PLACE: MUMBAI DATED: 29th October, 2026 Colinz COLINZ LABORATORIES LIMITED. , (CIN NO: L24200MH1986PLC041128) A·lOl, Pratik Indu;trlal Estate, Next to Fortis Hospital, Mulund·Goregaon Link Road, Mumbal-400078. AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED· 30th SEPTEMBER, 2026· "(Rs. In Lakhs)" Un·Audited Audited S. No. Particulars Quarter ended Six Month Ended Year Ended 30.Sep·26 30"un·26 30·Sep·25 30·Sep·26 30·Sep·25 3l·Mar·26 PART·' 1 (a) Revenue from Operation 155.00 124.09 138.80 279.09 295.41 613.61 3 (b) Other Income 13.91 12.17 15.93 26.08 23.45 48.44 3 Total Income from Operation 168.91 136.26 154.73 305.17 318.86 662.05 4 Expenses (a) Cost Of Material Consumed 9.08 10.93 16.26 20.01 34.99 57.05 (b) Purchase of Stock in Trade 39.42 30.06 17.89 69.49 60.57 112.48 (c) Change in Inventories Of Finished Goods and Work in Progress and Stock in Trade 8.42 (18.80) (8.52) (10.39) (29.96) 1.50 (d) Employee Benefit Expenses 61.50 63.58 75.92 125.08 141.63 269.56 (e) Finance Cost 1.55 0.73 1.31 2.28 2.47 4.66 (I) Depreciation & Amortisation Expenses 1.90 3.91 3.91 5.81 7.81 15.63 (g) Other Expenses 28.39 32.06 29.31 60.45 66.63 132.26 Total Expenses 150.26 122.47 136.08 272.73 284.14 593.14 EPr xo cH ept t! io(L nao ls is t) mB se fore exceptional Items and tax (3,4) 18 .65 13 .79 1 ·8 .65 32-.44 3 ·4 .72 68.91 I) Profit on Sale of Fixed Assets(Net) · 276.33 276.33 · 7 ProHt !(Loss) before tax (5·6) 18.65 290.12 18.65 308.77 34.72 68.91 8 Tax Expenses ( Provision for Taxation) Current tax I ii) C Du er fr fe en ret dT a Tx 6 -.00 50 -.00 4 -.60 56 -.00 8 -.75 [1 19 .5.0 40 iii) Tax for earlier years - · · . · Iv) MAT Credit of Earlier years · · · . · 9 ProHt !(Loss) for the period from continuIng operatlons(7'8) 12.65 240.12 14.05 252.77 25.97 51.45 10 Profit! (Loss) for the period 12.65 240.12 14.05 252.77 25.97 51.45 11 Other Comprehensive Income (Net of Tax) A) Item that will not be reclassified to Profit or Loss Account i) Change in fair value of investment in Equity Instruments 0.14 13.66 5.15 13.80 14.28 5.42 12 Total Comprehensive Income for the period (10+11) Comprising 12.79 253.78 19.20 266.57 40.25 56.87 13 Earning per equity share (for Continuing operation) (In Rs.) I) Basic 0.50 9.53 0.56 10.03 1.03 2.04 ii) Diluted - 0.50 9.53 0.56 10.03 1.03 2.04 ,,~...M.ut~4 . Co "-'--...QAloratortes Limited CIN NO- L24200MH 19 86PLC04 11 28 Corp.Off.: Al101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai _ 400078. INDIA E-mail: colinzlabs@yahoo.com!colinzlabs@gmail.com Mobile: 9137392123 Colinz STATEMENT OF ASSETS AND LIABILITIES "(Rs.ln Lakhs)" Particulars 30-Seo-Z6 31-Mar-ZOZ6 Non-Current Assets a) Property. Plants & Equipment 42.61 154.43 b) Capital Work-in progress c) Intangible Assets - - d) Financial Assets i) Investments 126.40 110.63 ii) Loans iii) Other Financial Assets e) Other Non Current Assets 2.34 5.41 Total Non-Current Assets 171.35 270.47 Current Assets a) Inventories 82.99 70.35 b) Financial Assets i) Trade Receivables 90.92 83.51 ii) Cash & Cash Equivalents 41.95 70.34 iii) Other Bank Balances 1085.30 782.57 iv) Other Financial Assets c) Other Current Assets 1.13 0.91 Total Current Assets 1302.29 1007.68 TOTAL ASSETS 1473.64 1278.15 EQUITY AND LIABILITIES Equity a) Equity Share Capital 251.91 251.91 b) Other Equity 1018.97 752.40 Total Equity 1270.88 1004.31 Liabilities Non-Current Liabilities a) Deferred Tax Liabilities ( Net) 19.26 17.29 b) Othet Non Current Liabilities - - Total Non-Current Liabilities 19.26 17.29 Current LIabilities a) Financial Liabilities i) Borrowings 45.23 38.99 Ii) Trade Payables 46.83 38.26 b) Other Current Liabilities 56.22 166.08 c) Current Provisions 35.22 13.22 Total Current Liabilities - ., 183.50 256.55 TOTAL EQUITY AND UABILmES 1473.64- 1278.15 "1U -M>€ l>- Colinz Laboratories Limited CIN NO- L24200MH1986PLC041128 Corp.Off.: Al101. Pratik Estate. Next to Fortis Hospital. Mulund Link Road, P. Box No. 17339 Mumbai -400 078. INDIA E-mail : colinzlabs@yahoo.com/colinzlabs@gmail.co [Showing first 8,000 characters — download PDF for full document]